Vanguard disaggregates holdings after Jan 12, 2026 realignment; reports 0 shares in Chemours (CC)
Rhea-AI Filing Summary
Chemours Co/The — The Vanguard Group filed Amendment No. 11 to its Schedule 13G/A reporting beneficial ownership of 0 shares (0%) of Chemours common stock. The filing states that an internal realignment effective January 12, 2026 caused certain Vanguard subsidiaries/divisions to report holdings separately in reliance on SEC Release No. 34-39538.
The filing is signed by Ashley Grim, Head of Global Fund Administration on 03/26/2026 and lists Vanguard's principal business office in Malvern, Pennsylvania.
Positive
- None.
Negative
- None.
FAQ
What does Vanguard report for Chemours (CC) ownership in this amendment?
Why are Vanguard subsidiaries reporting separately for Chemours (CC)?
Who signed the Schedule 13G/A amendment for Vanguard on Chemours (CC)?
Does this amendment show any Vanguard voting or dispositive power for Chemours (CC)?
Is the 0-share report for Chemours (CC) tied to a change in reporting method?